Literature DB >> 28689694

Is restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion?

François Audenet1, Caitlyn Retinger1, Christine Chien2, Nicole E Benfante1, Bernard H Bochner1, S Machele Donat1, Harry W Herr1, Guido Dalbagni3.   

Abstract

OBJECTIVES: To evaluate the influence of lamina propria invasion type at initial transurethral resection (TUR) on restaging pathology.
MATERIALS AND METHODS: We reviewed prospectively maintained records of all patients with a high-grade pT1 nonmuscle invasive bladder cancer who underwent both initial and restaging TUR within 6 weeks at our center between 2001 and 2016. The pathology of second TUR specimens was analyzed with regard to the characteristics of lamina propria invasion found at initial resection.
RESULTS: We included 198 patients, with a median age of 70 years (interquartile range: 63-79). Muscle was present in the initial TUR specimen in 107 patients (54%). Pathology restaging was pT0 in 73 patients (37%), pTis in 44 (22%), pTa in 27 (14%), pT1 in 50 (25%), and pT2 in 4 (2%). Eighty-seven patients (44%) had tumors with minimal lamina propria invasion at initial TUR: 53 specimens (27%) had focal invasion (few malignant cells in the lamina propria); 15 specimens (7.6%) had superficial invasion (invasion of the lamina propria to the level of the muscularis mucosae [T1a]); and 19 specimens (10%) had multifocal superficial invasion (multiple areas of T1a). Of the patients with minimal lamina propria invasion, residual disease was found in 54 patients (62%). However, none of those patients had T2 disease.
CONCLUSIONS: A significant number of patients with T1 tumors have residual disease at restaging TUR as do patients with minimal lamina propria invasion. The extent of T1 invasion does not eliminate the need for repeat TUR.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Diagnosis; Prognosis; Transurethral resection; Urothelial carcinoma

Mesh:

Year:  2017        PMID: 28689694      PMCID: PMC5643222          DOI: 10.1016/j.urolonc.2017.06.042

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  29 in total

1.  Evaluation of second-look transurethral resection in restaging of patients with nonmuscle-invasive bladder cancer.

Authors:  Mohamed H Ali; Iman Y Ismail; Ahmad Eltobgy; Ammar Gobeish
Journal:  J Endourol       Date:  2010-10-08       Impact factor: 2.942

Review 2.  Repeated white light transurethral resection of the bladder in nonmuscle-invasive urothelial bladder cancers: systematic review and meta-analysis.

Authors:  Alberto Vianello; Elisabetta Costantini; Michele Del Zingaro; Vittorio Bini; Harry W Herr; Massimo Porena
Journal:  J Endourol       Date:  2011-09-21       Impact factor: 2.942

3.  The value of a second transurethral resection for T1 bladder cancer.

Authors:  Hartwig E Schwaibold; Sivaprakasam Sivalingam; Florian May; Rudolf Hartung
Journal:  BJU Int       Date:  2006-03-23       Impact factor: 5.588

4.  Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients.

Authors:  Paolo Gontero; Richard Sylvester; Francesca Pisano; Steven Joniau; Kathy Vander Eeckt; Vincenzo Serretta; Stéphane Larré; Savino Di Stasi; Bas Van Rhijn; Alfred J Witjes; Anne J Grotenhuis; Lambertus A Kiemeney; Renzo Colombo; Alberto Briganti; Marek Babjuk; Per-Uno Malmström; Marco Oderda; Jacques Irani; Nuria Malats; Jack Baniel; Roy Mano; Tommaso Cai; Eugene K Cha; Peter Ardelt; John Varkarakis; Riccardo Bartoletti; Martin Spahn; Robert Johansson; Bruno Frea; Viktor Soukup; Evanguelos Xylinas; Guido Dalbagni; R Jeffrey Karnes; Shahrokh F Shariat; Joan Palou
Journal:  Eur Urol       Date:  2014-07-16       Impact factor: 20.096

Review 5.  Epidemiology and risk factors of urothelial bladder cancer.

Authors:  Maximilian Burger; James W F Catto; Guido Dalbagni; H Barton Grossman; Harry Herr; Pierre Karakiewicz; Wassim Kassouf; Lambertus A Kiemeney; Carlo La Vecchia; Shahrokh Shariat; Yair Lotan
Journal:  Eur Urol       Date:  2012-07-25       Impact factor: 20.096

6.  Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early?

Authors:  A Brauers; R Buettner; G Jakse
Journal:  J Urol       Date:  2001-03       Impact factor: 7.450

7.  [T1 high-grade bladder cancer - value of second operation with prognostuic parameters of first operation: analysis of 167 cases].

Authors:  D A Lazica; S Böttcher; S Degener; F-C von Rundstedt; A S Brandt; S Roth; S Störkel; M J Mathers
Journal:  Aktuelle Urol       Date:  2013-04-11       Impact factor: 0.658

8.  Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies.

Authors:  Maurizio Brausi; Laurence Collette; Karlheinz Kurth; Adrian P van der Meijden; Wim Oosterlinck; J A Witjes; Donald Newling; Christian Bouffioux; Richard J Sylvester
Journal:  Eur Urol       Date:  2002-05       Impact factor: 20.096

9.  Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder.

Authors:  R Klän; V Loy; H Huland
Journal:  J Urol       Date:  1991-08       Impact factor: 7.450

10.  Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients.

Authors:  A Orsola; L Werner; I de Torres; W Martin-Doyle; C X Raventos; F Lozano; S A Mullane; J J Leow; J A Barletta; J Bellmunt; J Morote
Journal:  Br J Cancer       Date:  2014-12-23       Impact factor: 7.640

View more
  3 in total

1.  The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial.

Authors:  Askin Eroglu; Rahmi Gokhan Ekin; Gokhan Koc; Rauf Taner Divrik
Journal:  Int J Clin Oncol       Date:  2019-11-23       Impact factor: 3.402

2.  Does restaging transurethral resection of bladder tumour influence outcomes in patients treated with BCG immunotherapy? 491 cases in 20 years' experience.

Authors:  Wojciech Krajewski; Romuald Zdrojowy; Katarzyna Kościelska-Kasprzak; Janusz Dembowski; Michał Wróbel; Mateusz Łuczak; Anna Kołodziej
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2018-12-19       Impact factor: 1.195

3.  Identification of potential prognostic factors for absence of residual disease in the second resection of T1 bladder cancer.

Authors:  Anna Katarzyna Czech; Katarzyna Gronostaj; Jakub Frydrych; Jakub Fronczek; Mikołaj Przydacz; Tomasz Wiatr; Łukasz Curyło; Przemysław Dudek; Jerzy Gąsowski; Piotr L Chłosta
Journal:  Cent European J Urol       Date:  2019-09-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.